Skip to main content

Latest SEC Filings — Page 161

Most recent SEC EDGAR filings across all covered tickers, sorted chronologically. Wiseek AI reads each filing and scores it 1–10 for market-moving potential; click through for full analysis.

How Wiseek curates this list

Every filing on this page is sourced directly from SEC EDGAR, the U.S. Securities and Exchange Commission's public filings system. Wiseek processes 8-K, 10-K, 10-Q, Form 4, Form 144, DEF 14A, Schedule 13D/A and related disclosures filed by U.S.-listed companies. The original filing is always linked from each article so readers can verify the source document directly.

How filings get scored

Each filing runs through Wiseek's importance scorer, which weights filing type, deal magnitude, insider participation, material-event flags (going-concern, restatements, executive transitions, M&A) and historical market-reaction patterns. Filings scoring below 7 on the 1–10 scale are filtered out at the database query so this list stays focused on market-moving disclosures. See our methodology for the full rubric.

Editorial standards

Wiseek does not edit the underlying SEC filing. Plain-English summaries and key-event extractions are generated from the verified source text and clearly attributed as AI-generated. Wiseek does not provide investment advice — see our editorial policy for full standards on accuracy, source disclosure, and corrections.

Track by company

Follow all SEC filings for a specific company by visiting its ticker page: AAPL, MSFT, NVDA, TSLA, AMZN, GOOGL, META, JPM, V, UNH, XOM, AVGO, LLY, MA, COST, JNJ, PG, HD, ABBV, MRK, KO, NFLX, AMD, WMT, CVX, BAC — or browse all covered tickers.

Jianzhi Education Prices $5.4M Direct Offering at $0.45/ADS, Deep Discount to Market
ProForm 424B5JZ · Form 424B5 · 2026-08-14
Partner Doses First Patient in Phase 2 IgAN Trial
Form 8-KCLYM · Form 8-K · 2026-08-14
Jianzhi Education Prices $5.4M Registered Direct Offering at $0.45/ADS — 82% Below Market
ProForm 6-KJZ · Form 6-K · 2026-08-14
Our Bond Flags $3M Government Contract Likely to Fall Through in Q2 Webinar
Form 8-KOBAI · Form 8-K · 2026-08-14
SpaceX Closes $60B Anysphere Acquisition, Issuing 389M Shares
ProForm 8-KSPCX · Form 8-K · 2026-08-14
Quince Therapeutics Posts Q2 Loss of $12.31/Share, Extends Cash Runway to 2028
Form 8-KQNCX · Form 8-K · 2026-08-14
Dragonfly Energy Q2 2026: Net Loss Narrows to $4.4M, Going Concern Doubt Alleviated, Dakota Lithium Deal Closes
ProForm 10-QDFLI · Form 10-Q · 2026-08-14
IPDN 10-Q: Going Concern, Nasdaq Delisting Risk, and $3.57M Loss
ProForm 10-QIPDN · Form 10-Q · 2026-08-14
Agape ATP Q2 2026: Going Concern, 98% of Assets Trapped in China Deposit
ProForm 10-QATPC · Form 10-Q · 2026-08-14
Aptevo Q2 2026: $13.1M Loss, Going Concern Warning, and $4.5M Financing
ProForm 10-QAPVO · Form 10-Q · 2026-08-14
Suncrete Q2 Revenue Jumps 146% to $97.2M, Net Loss Widens to $37.1M
Form 8-KRMIX · Form 8-K · 2026-08-14
Director Troim Tor Olav Buys $6M of Borr Drilling Stock
Form 4BORR · Form 4 · 2026-08-14
Replimune Posts Q1 Loss, Appoints Chief Commercial Officer Ahead of TUDRIQEV Launch
Form 8-KREPL · Form 8-K · 2026-08-14
Aptevo's Q2 2026 Update: Compelling AML Data, New CSO, and Niowave's Equity Stake
Form 8-KAPVO · Form 8-K · 2026-08-14
Coherent FY26 10-K: Revenue up 23% to $7.1B, NVIDIA $2B investment, preferred stock eliminated
ProForm 10-KCOHR · Form 10-K · 2026-08-14
Our Bond Q2 Loss Widens to $4.8M; Going Concern Warning Reiterated
ProForm 10-QOBAI · Form 10-Q · 2026-08-14
BTQ Q2 Update: QSSN Hits 100K Mainnet Transactions, QCIM Benchmarks Revealed
Form 6-KBTQ · Form 6-K · 2026-08-14
Allarity Q2: $26.9M Cash, $20M Debt, and a CLIA Lab Milestone
Form 10-QALLR · Form 10-Q · 2026-08-14
Clene Q2 2026: Going Concern Warning, Material Weaknesses, and $21.5M Loss
ProForm 10-QCLNN · Form 10-Q · 2026-08-14
GT Biopharma Q2 Loss Narrows, But Going Concern and Nasdaq Delisting Risks Persist
ProForm 10-QGTBP · Form 10-Q · 2026-08-14
BIO-key Q2 Loss Narrows 51% on 13% Revenue Growth; $2.5M Warrant Exercise Boosts Cash
Form 8-KBKYI · Form 8-K · 2026-08-14
1847 Holdings Reiterates Going Concern Doubt, CMD Sale Process Ongoing
ProForm 10-QLBRA · Form 10-Q · 2026-08-14
Quantum Cyber Flags Going Concern Doubt, Material Weakness, and $16.1M Loss
ProForm 10-QQUCY · Form 10-Q · 2026-08-14
Genvor 10-Q Reveals $1.6M Tax Reimbursement Liability and New Material Weaknesses
ProForm 10-QGNVR · Form 10-Q · 2026-08-14
Outlook Therapeutics Posts Q3 Loss and Unveils $51M Offering to Back LYTENAVA Launch
ProForm 8-KOTLK · Form 8-K · 2026-08-14
Nuvera Q2 Loss Narrows, But Debt Covenant Breach Forces Waiver
Form 10-QNUVR · Form 10-Q · 2026-08-14
VerifyMe Q2 Revenue Falls 58%, Nasdaq Delisting Notice Disclosed
ProForm 10-QVRME · Form 10-Q · 2026-08-14
TuHURA Q2 2026: $1.0M Cash, $50M Credit Facility Draws, CEO 10b5-1 Plan
Form 10-QHURA · Form 10-Q · 2026-08-14
Lightwave Logic Q2 Loss Widens 33% as R&D Spend Jumps; Cash Runway Extended to Dec 2027
Form 10-QLWLG · Form 10-Q · 2026-08-14
PMV Pharma Flags Going Concern Doubt as Cash Drops to $79.4M
ProForm 10-QPMVP · Form 10-Q · 2026-08-14